Provided by Tiger Fintech (Singapore) Pte. Ltd.

The India Fund Inc

14.87
+0.10000.68%
Volume:108.32K
Turnover:1.61M
Market Cap:557.61M
PE:3.25
High:14.95
Open:14.84
Low:14.74
Close:14.77
Loading ...

abrdn U.S. Closed-End Funds Announce Distribution Payment Details

ACCESS Newswire
·
12 Feb

Cyprium Metals Advances Nifty Copper Project with Macmahon Partnership

TIPRANKS
·
05 Feb

Cyprium Metals Advances Nifty Copper Project with Strategic Initiatives

TIPRANKS
·
30 Jan

Cyprium Metals Partners with Macmahon for Nifty Redevelopment

TIPRANKS
·
23 Jan

Cyprium Metals Forms Strategic Alliance with Macmahon to Boost Nifty Redevelopment

TIPRANKS
·
23 Jan

Arbutus Provides 2025 Corporate and Financial Update

GlobeNewswire
·
13 Jan

Indian Stocks Outperform Biggest Asian Peers at Start of 2025

Bloomberg
·
02 Jan

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

GlobeNewswire
·
10 Dec 2024

Nifty Bulls Eye 25,000 As Hopes Rise For RBI Easing Rate

Bloomberg
·
06 Dec 2024

Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

GlobeNewswire
·
05 Dec 2024

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024

GlobeNewswire
·
03 Dec 2024

Nifty Set For Back-to-Back Monthly Losses For The First Time Since Early 2023

Bloomberg
·
29 Nov 2024

Cyprium Metals Poised for Growth with Nifty Copper Advances

TIPRANKS
·
28 Nov 2024

Cyprium Metals Unveils Promising Nifty Copper Study

TIPRANKS
·
27 Nov 2024

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

GlobeNewswire
·
16 Nov 2024

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

GlobeNewswire
·
16 Nov 2024